BRADENTON, Fla.–(BUSINESS WIRE)–PaceMate™ is pleased to announce that as of August 15, 2018, the Arizona Heart Rhythm Center will be the first organization in the state of Arizona to offer automated remote monitoring of cardiac implantable electronic devices (CIEDs) such as pacemakers, defibrillators, and loop recorders via the PaceMate™ software […]
Other News
BioSig Technologies Announces FDA 510(k) Clearance for PURE EP System
Santa Monica, CA, Aug. 14, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), announced that the Company has received 510(k) clearance for its first product, PURE EP System, from the U.S. Food and Drug Administration (FDA). The non-invasive PURE EP System is a computerized system intended for acquiring, digitizing, amplifying, filtering, measuring […]
Avinger Announces Second Quarter 2018 Financial Results
REDWOOD CITY, Calif., Aug. 13, 2018 (GLOBE NEWSWIRE) — Avinger, Inc. (Nasdaq: AVGR), a leading developer of innovative treatments for peripheral artery disease (PAD), today reported results for the second quarter ended June 30, 2018. Second Quarter and Recent Highlights Revenue of $2.1 million for the second quarter of 2018, […]
Catasys to Announce Second Quarter 2018 Results and Host Conference Call on August 14, 2018
LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced that the Company will be releasing financial results for its second quarter and six months ended June 30, 2018, after the closing of the stock market on Tuesday, August 14, 2018. The Company […]
Itamar Medical Reports Second Quarter 2018 Financial Results
CAESAREA, Israel, Aug. 13, 2018 (GLOBE NEWSWIRE) — Itamar Medical Ltd. (TASE: ITMR), a company that develops, manufactures, and markets non-invasive diagnostic medical devices for sleep-apnea with a focus on the cardiology market, today reported financial results for the second quarter of 2018. “Itamar Medical continues to demonstrate double-digit growth […]
BioSig Technologies Completes Private Placement
Santa Monica, CA, Aug. 13, 2018 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (OTCQB: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the $4.6 billion electrophysiology (EP) marketplace, today announced that the Company closed a private placement of $4,281,000. Combined with the […]
Medicure Announces FDA Approval of Acute Care Cardiovascular Drug Sodium Nitroprusside Injection
WINNIPEG, Aug. 13, 2018 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH, OTC:MCUJF), a cardiovascular pharmaceutical company, is pleased to announce that the United States Food and Drug Administration (“FDA”) has approved its Abbreviated New Drug Application (“ANDA”) for Sodium Nitroprusside Injection 50 mg/2 mL (25 mg/mL) single dose vial (“SNP”), […]
Advanced Cardiac Therapeutics, Inc. Changes Name to EPIX Therapeutics, Inc.
SANTA CLARA, Calif., Aug. 13, 2018 /PRNewswire/ — Advanced Cardiac Therapeutics, Inc. (ACT), a medical device company that designs and manufactures a catheter-based system for the treatment of patients with atrial fibrillation (AFIB), today announced it has changed its name to EPIX Therapeutics, Inc. Founded in 2007, the company has pioneered the development […]
Endologix Reports Second Quarter 2018 Financial Results
IRVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (NASDAQ:ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the second quarter ended June 30, 2018. The Company reported global revenue of $44.7 million in the second quarter of 2018, a decrease of 7.9% from $48.6 million in the second […]
ARCA biopharma Announces Second Quarter 2018 Financial Results and Provides Corporate Update
WESTMINSTER, Colo., Aug. 09, 2018 (GLOBE NEWSWIRE) — ARCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today reported financial results for the quarter ended June 30, 2018. “The second quarter of this year saw an important milestone for the […]